Log in

Relevant bibliographies by topics / Edaravon / Journal articles

To see the other types of publications on this topic, follow the link: Edaravon.

Journal articles on the topic 'Edaravon'

Author: Grafiati

Published: 5 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Edaravon.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kobeliatskyi, Yu Yu. "Management of acute ischemic stroke in the practice of anesthesiologist." Infusion & Chemotherapy, no. 3.2 (December 15, 2020): 126–28. http://dx.doi.org/10.32902/2663-0338-2020-3.2-126-128.

Full text

Abstract:

Background. Stroke is a major cause of severe disability. Working capacity is restored only in 10-20 % of stroke survivors. Stroke mortality in Ukraine is twice as high as in Western Europe. About 87 % of all strokes are ischemic strokes (II). Leading risk factors for stroke include hypertension, hypercholesterolemia, smoking, obesity, and diabetes. Objective. To describe the management of acute IS (AIS) in the practice of an anesthesiologist. Materials and methods. Analysis of literature data on this issue. Results and discussion. The ideal therapeutic approach for AIS shoul

APA, Harvard, Vancouver, ISO, and other styles

2

Vdovychenko, Yuriy P., Oleg A. Loskutov, Oleksandr A. Halushko, et al. "ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE." Wiadomości Lekarskie 74, no. 1 (2021): 72–76. http://dx.doi.org/10.36740/wlek202101114.

Full text

Abstract:

The aim: To investigate the effectiveness of usage of the free radical scavenger Edaravone in the therapy of women with AIS. Materials and methods: A prospective study was conducted of 48 women with AIS, divided into two groups. Patients in the first group (n = 36) were treated with edaravone 30 mg twice a day intravenously. Neuroprotectors were not used in the control group (n = 12). Clinical-instrumental and neurological examination (Glasgow scale (SCG), FOUR, NIHSS, and neuronspecific enolase (NSE) levels) were performed on all patients. Results: The mean FOUR score in the 1th group increas

APA, Harvard, Vancouver, ISO, and other styles

3

Ivanov, D. D., M. D. Ivanova, and I. I. Burlachenko. "Edaravone in contrast-induced acute kidney injury prophelaxis." Ukrainian Journal of Cardiology 27, no. 1 (2020): 39–44. http://dx.doi.org/10.31928/1608-635x-2020.1.3944.

Full text

Abstract:

The aim – to evaluate the effectiveness of edaravon in preventing the development of contrast-induced acute kidney injury. Materials and methods. We have conducted a multicenter open prospective randomized controlled study to evaluate the efficacy of edaravone in preventing contrast-induced acute kidney injury in patients with chronic kidney disease (CKD) 3b–4 stages. The study included 2 groups of patients aged 46 to 68 (55±3): group A (n=16) with CKD stage 3b or 4 (еstimated glomerular filtration rate (formula СКD-EPI) 32±4 ml/min) that received intravenous edaravone 30 mg bid on 0, 1, 2 day

APA, Harvard, Vancouver, ISO, and other styles

4

Kyrychenko, O. V., and S. P. Moskovko. "A modern view of approaches of neuroprotective therapy in patients with ischemic stroke. Review." Ukrainian Neurological Journal, no. 1—2 (July 1, 2022): 12–16. http://dx.doi.org/10.30978/unj2022-1-12.

Full text

Abstract:

Timely use of neuroprotectors for treatment of ischemic stroke should prevent or inhibit the pathogenetic mechanisms that lead to apoptosis of brain cells, both in the nucleus of the infarct and in the ischemic penumbra. The concept of neuroprotection has a sufficient scientific basis, but the questions of its effectiveness, safety and optimal points of application remain controversial, taking into account the available results of clinical trials. Currently, two pharmacological agents are most commonly used as neuroprotective agents in ischemic stroke (IS) — Cerebrolysin and Edaravon (in the U

APA, Harvard, Vancouver, ISO, and other styles

5

Chaudhuri, Pratyush. "Edaravon: Caution for use in traumatic brain injury. Experience in 127 patients." Indian Journal of Neurotrauma 10, no. 1 (2013): 19–23. http://dx.doi.org/10.1016/j.ijnt.2013.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ahire, Snehal, Ankita Deo, Sayali Marathe, and Tania Bose. "Pathophysiology of neurodegenerative disease and available treatments: Amyotrophic lateral sclerosis." INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES 76, no. 03 (2024): 8–13. https://doi.org/10.55184/ijpas.v76i03.267.

Full text

Abstract:

Amyotrophic lateral Sclerosis (ALS) is an adult-onset neurogenerative disease. It affects the motor neurons resulting in muscle weakness and causing death of the patient. Multiple factors like genetic, environmental, as well as age involved in the etiopathogenesis of ALS. ALS is a highly complex and equally challenging disease that involves various pathogenesis linked with progressive motor neuron degeneration, it is difficult to have a single therapeutic target against the disease. Till date only a few drugs have been FDA-approved, while many are still under clinical trials. Hence reducing th

APA, Harvard, Vancouver, ISO, and other styles

7

Lynnyk, М. І., V. І. Іgnatieva, G. L. Gumeniuk, et al. "Evaluation of the treatment efficacy in the patients with viral etiology community acquired pneumonia (COVID-19) with the use of syndrome-pathogenetic small volume infusion therapy according to computer tomography data." Infusion & Chemotherapy, no. 2 (June 29, 2021): 31–38. http://dx.doi.org/10.32902/2663-0338-2021-2-31-38.

Full text

Abstract:

BACKGROUND. In a pandemic, when the etiotropic therapy of SARS-CoV-2 has not yet been developed, a comprehensive individual syndrome-pathogenetic approach to the treatment of patients with community-acquired pneumonia of viral etiology (COVID-19) is extremely important. The search for new commonly available drugs that can affect the inhibition of the cytokine storm, eliminate endothelial dysfunction and accelerate reparative processes in the lungs is relevant. At the same time the parenteral way of administration of the drugs provides the maximum bioavailability. OBJECT. To evaluate the

APA, Harvard, Vancouver, ISO, and other styles

8

Юрко, Е. В., В. В. Кучерявченко, А. О. Соломенник, and А. С. Лесная. "Methods for Correction of Neurological Diseases in Patients with Coronaviral Disease (Covid-19)." Клиническая инфектология и паразитология, no. 2 (November 4, 2021): 162–72. http://dx.doi.org/10.34883/pi.2021.10.2.022.

Full text

Abstract:

Цель работы. Проанализировать частоту возникновения и спектр неврологических нарушений у пациентов с коронавирусной болезнью, совершенствование патогенетического лечения. Материалы и методы. Обследовано 83 пациента с коронавирусной болезнью, госпитализированных в КНП ХОР «Областная клиническая инфекционная больница» за период с мая по декабрь 2020 г. Пациенты были поделены на группы в зависимости от степени тяжести болезни и в зависимости от назначенной терапии. Всем пациентам до начала лечения и после его окончания определяли показатели протеинограммы, в частности содержание общего белка иаль

APA, Harvard, Vancouver, ISO, and other styles

9

Xodjieva, Dilbar Tojiyevna, and Zarnigor Hikmatovna Nurova. "EFFICACY OF NEUROPROTECTIVE DRUGS IN ACUTE REPERFUSION CARDIOEMBOLIC STROKE." Journal of neurology and neurosurgical research 3, no. 4 (2022): 5. https://doi.org/10.5281/zenodo.7112775.

Full text

Abstract:

Stroke is the leading cause of disability and the second most common cause of death worldwide. Accurate determination of the mechanism of stroke is crucial, because the most effective care and therapy depend on it. Cardioembolic stroke accounts for 14-30% of all cerebral infarcts. In most cases, recurrence of cardioembolic stroke can be prevented with oral anticoagulants. Therefore, early confirmation of the diagnosis of cardioembolic infarction is extremely important for the patient with cerebral infarction to start anticoagulant therapy for adequate secondary prevention.

APA, Harvard, Vancouver, ISO, and other styles

10

Lynnyk, М. І., L. A. Iashyna, V. І. Іgnatieva, et al. "Peculiarities of Viral Etiology (COVID-19) Community-aquired Pneumonia in Patients with Bronchial Asthma." Asthma and allergy 2022, no. 1-2 (2022): 15–26. http://dx.doi.org/10.31655/2307-3373-2022-1-2-15-26.

Full text

Abstract:

Abstract. Materials and methods. Analyzed in the dynamics CT OGK in 70 patients with community-acquired pneumonia of viral etiology (COVID-19), who were treated at the State Institution “National Institute of Tuberculosis and Pulmonology named after F. G. Yanovsky NAMS of Ukraine» in the acute period of the disease, including patients with concomitant asthma. CT OGK was performed on a scanner Aquilion TSX101A «Tochiba» (Japan). Spirography with analysis of the «flow-volume» curve of forced exhalation was performed on the «Master Screen Pneumo» and «Master Screen PFT», «Cardinal Health» (German

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Edaravone." Reactions Weekly &NA;, no. 1155 (2007): 9. http://dx.doi.org/10.2165/00128415-200711550-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Graul, A., and J. Castañer. "Edaravone." Drugs of the Future 21, no. 10 (1996): 1014. http://dx.doi.org/10.1358/dof.1996.021.10.376470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Brooks, Benjamin Rix, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang, and Stephen Apple. "Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]." PLOS ONE 17, no. 6 (2022): e0258614. http://dx.doi.org/10.1371/journal.pone.0258614.

Full text

Abstract:

Background Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19). One of the Study 19 inclusion criteria was forced vital capacity (FVC) ≥80% of predicted (≥80%p). Therefore, the study provided no information on edaravone efficacy in subjects with FVC <80%p. In Study 19, 24-week, double-blind treatment was followed by open-label treatment where all subjects received edaravone. At 24 weeks, some subjects had FVC <80%p (FVC24 <80%p). This allowed for post-hoc assessment of the effects of edaravone in su

APA, Harvard, Vancouver, ISO, and other styles

14

Xu, Jie, Anxin Wang, Xia Meng, et al. "Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke." Stroke 52, no. 3 (2021): 772–80. http://dx.doi.org/10.1161/strokeaha.120.031197.

Full text

Abstract:

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria includ

APA, Harvard, Vancouver, ISO, and other styles

15

Lyu, Yangting, and Bin Xu. "Efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole in the treatment of acute cerebral infarction: A systematic review and meta-analysis." Medicine 103, no. 44 (2024): e40223. http://dx.doi.org/10.1097/md.0000000000040223.

Full text

Abstract:

Background: To evaluate the clinical efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole (GLED) versus edaravone alone in the treatment of acute cerebral infarction (ACI) by the method of meta-analysis. Methods: PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, WANFANG DATA, and Chinese Scientific Journal Database were searched to identify publications on edaravone combined with GLED for ACI from inception to June 20, 2024. Stata15.0 statistical software was applied for data analysis. The test group was treated with edaravone com

APA, Harvard, Vancouver, ISO, and other styles

16

Uchida, Haruhito A., Tetsuharu Takatsuka, Yoshiko Hada, et al. "Edaravone Attenuated Angiotensin II-Induced Atherosclerosis and Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice." Biomolecules 12, no. 8 (2022): 1117. http://dx.doi.org/10.3390/biom12081117.

Full text

Abstract:

Background: The aim of the study was to define whether edaravone, a free-radical scavenger, influenced angiotensin II (AngII)-induced atherosclerosis and abdominal aortic aneurysms (AAAs) formation. Methods: Male apolipoprotein E-deficient mice (8–12 weeks old) were fed with a normal diet for 5 weeks. Either edaravone (10 mg/kg/day) or vehicle was injected intraperitoneally for 5 weeks. After 1 week of injections, mice were infused subcutaneously with either AngII (1000 ng/kg/min, n = 16–17 per group) or saline (n = 5 per group) by osmotic minipumps for 4 weeks. Results: AngII increased systol

APA, Harvard, Vancouver, ISO, and other styles

17

O’Neill, Riuna, Okhee Yoo, Philip Burcham, and Lee Yong Lim. "Edaravone for the Treatment of Motor Neurone Disease: A Critical Review of Approved and Alternative Formulations against a Proposed Quality Target Product Profile." Pharmaceutics 16, no. 8 (2024): 993. http://dx.doi.org/10.3390/pharmaceutics16080993.

Full text

Abstract:

Edaravone is one of two main drugs for treating motor neurone disease (MND). This review proposes a specific quality target product profile (QTPP) for edaravone following an appraisal of the issues accounting for the poor clinical uptake of the approved IV and oral liquid edaravone formulations. This is followed by a review of the alternative oral formulations of edaravone described in the published patent and journal literature against the QTPP. A total of 14 texts published by six research groups on 18 novel oral formulations of edaravone for the treatment of MND have been reviewed. The alte

APA, Harvard, Vancouver, ISO, and other styles

18

Kang, Dong Wook, Ju Hee Kim, Kyung Min Kim, et al. "Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704." Pharmaceutics 13, no. 9 (2021): 1406. http://dx.doi.org/10.3390/pharmaceutics13091406.

Full text

Abstract:

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger approved for the treatment of amyotrophic lateral sclerosis, a fatal neuromuscular disease. Edaravone is administered as an intravenous infusion over 60 min for several treatment cycles. To ease the burden of patients and caregivers, the oral formulation of edaravone has been developed. The purpose of this study was to evaluate pharmacokinetics and tissue distribution of TEJ-1704, an edaravone oral prodrug, in male Sprague Dawley rats and beagle dogs. Animal experiments were conducted using Sprague Dawley rats and beag

APA, Harvard, Vancouver, ISO, and other styles

19

Wang, Guozuo, Xiaomei Zeng, Shengqiang Gong, et al. "Exploring the Mechanism of Edaravone for Oxidative Stress in Rats with Cerebral Infarction Based on Quantitative Proteomics Technology." Evidence-Based Complementary and Alternative Medicine 2022 (January 4, 2022): 1–21. http://dx.doi.org/10.1155/2022/8653697.

Full text

Abstract:

Objective. To explore the mechanism of edaravone in the treatment of oxidative stress in rats with cerebral infarction based on quantitative proteomics technology. Method. The modified Zea Longa intracavitary suture blocking method was utilized to make rat CI model. After modeling, the rat was intragastrically given edaravone for 7 days, once a day. After the 7-day intervention, the total proteins of serum were extracted. After proteomics analysis, the differentially expressed proteins are analyzed by bioinformatics. Then chemoinformatics methods were used to explore the biomolecular network o

APA, Harvard, Vancouver, ISO, and other styles

20

Cha, Sun Joo, and Kiyoung Kim. "Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection." Antioxidants 11, no. 2 (2022): 195. http://dx.doi.org/10.3390/antiox11020195.

Full text

Abstract:

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to treat amyotrophic lateral sclerosis. The distinguishing pathogenic features of neurodegenerative diseases include high reactive oxygen species levels and mitochondrial dysfunction. However, the correlation between mitochondria and edaravone has not been elucidated. This review highlights recent studie

APA, Harvard, Vancouver, ISO, and other styles

21

Ji, Lei, Yingying Liu, Ying Zhang, et al. "The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts." Canadian Journal of Physiology and Pharmacology 94, no. 9 (2016): 996–1006. http://dx.doi.org/10.1139/cjpp-2015-0587.

Full text

Abstract:

Edaravone, a radical scavenger, has been recognized as a potential protective agent for cardiovascular diseases. However, little is known about the effect of edaravone in cardiac complications associated with diabetes. Here, we have demonstrated that edaravone prevents cardiac dysfunction and apoptosis in the streptozotocin-induced type 1 diabetic rat heart. Mechanistic studies revealed that edaravone treatment improved cardiac function and restored superoxide dismutase levels. In addition, treatment of diabetic animals by edaravone increased protein expressions of sirtuin-1 (SIRT-1), peroxiso

APA, Harvard, Vancouver, ISO, and other styles

22

Ikeda, Satoshi, Katsuhiro Harada, Akihiko Ohwatashi, and Yurie Kamikawa. "Effects of Edaravone, a Free Radical Scavenger, on Photochemically Induced Cerebral Infarction in a Rat Hemiplegic Model." Scientific World Journal 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/175280.

Full text

Abstract:

Edaravone is a free radical scavenger that protects the adjacent cortex during cerebral infarction. We created a hemiparetic model of cerebral thrombosis from a photochemically induced infarction with the photosensitive dye, rose bengal, in rats. We examined the effects of edaravone on recovery in the model. A total of 36 adult Wistar rats were used. The right sensorimotor area was irradiated with green light with a wavelength of 533 nm (10 mm diameter), and the rose bengal was injected intravenously to create an infarction. The edaravone group was injected intraperitoneally with edaravone (3

APA, Harvard, Vancouver, ISO, and other styles

23

Kikuchi, Kiyoshi, Kentaro Setoyama, Ko-ichi Kawahara, et al. "Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis." Oxidative Medicine and Cellular Longevity 2017 (2017): 1–14. http://dx.doi.org/10.1155/2017/6873281.

Full text

Abstract:

The combination of alteplase, a recombinant tissue plasminogen activator, and edaravone, an antioxidant, reportedly enhances recanalization after acute ischemic stroke. We examined the influence of edaravone on the thrombolytic efficacy of alteplase by measuring thrombolysis using a newly developed microchip-based flow-chamber assay. Rat models of embolic cerebral ischemia were treated with either alteplase or alteplase-edaravone combination therapy. The combination therapy significantly reduced the infarct volume and improved neurological deficits. Human blood samples from healthy volunteers

APA, Harvard, Vancouver, ISO, and other styles

24

Kuang, Jihui, Mingzhu Liu, Qing Yu, et al. "Antiviral Effect and Mechanism of Edaravone against Grouper Iridovirus Infection." Viruses 15, no. 11 (2023): 2237. http://dx.doi.org/10.3390/v15112237.

Full text

Abstract:

Singapore grouper iridovirus (SGIV) is a virus with high fatality rate in the grouper culture industry. The outbreak of SGIV is often accompanied by a large number of grouper deaths, which has a great impact on the economy. Therefore, it is of great significance to find effective drugs against SGIV. It has been reported that edaravone is a broad-spectrum antiviral drug, most widely used clinically in recent years, but no report has been found exploring the effect of edaravone on SGIV infections. In this study, we evaluated the antiviral effect of edaravone against SGIV, and the anti-SGIV mecha

APA, Harvard, Vancouver, ISO, and other styles

25

Omori, Kazuyoshi, Yasushi Shikata, Kei Sarai, et al. "Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells." American Journal of Physiology-Cell Physiology 293, no. 5 (2007): C1523—C1531. http://dx.doi.org/10.1152/ajpcell.00524.2006.

Full text

Abstract:

Edaravone is a potent scavenger of hydroxyl radicals and is quite successful in patients with acute cerebral ischemia, and several organ-protective effects have been reported. Treatment of human microvascular endothelial cells with edaravone (1.5 μM) resulted in the enhancement of transmonolayer electrical resistance coincident with cortical actin enhancement and redistribution of focal adhesion proteins and adherens junction proteins to the cell periphery. Edaravone also induced small GTPase Rac activation and focal adhesion kinase (FAK; Tyr576) phosphorylation associated with sphingosine-1-p

APA, Harvard, Vancouver, ISO, and other styles

26

Bagheri, Yasin, Mahshid Dehghan, Seyyedeh Mina Hejazian, Mohammadreza Ardalan, Sepideh Zununi Vahed, and Bahram Niknafs. "The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model." Journal of Cardiovascular and Thoracic Research 16, no. 4 (2024): 243–48. https://doi.org/10.34172/jcvtr.33077.

Full text

Abstract:

Introduction: Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction. This study aimed to investigate the antioxidative effects of Edaravone on cardiac tissues following the induction of renal ischemia-reperfusion injury (IRI) in rats. Methods: Twenty-four male Wistar rats were randomly divided into four groups: IR+Edaravone, Edaravone, IR, and Sham groups (six rats per group). Non-traumatic clamps were used to stop the artery and vein blood flow of the left kidney in ra

APA, Harvard, Vancouver, ISO, and other styles

27

Kawamoto, Terufumi, and Keisuke Sasai. "Edaravone Exerts Protective Effects on Mice Intestinal Injury without Interfering with the Anti-Tumor Effects of Radiation." Current Issues in Molecular Biology 45, no. 7 (2023): 5362–72. http://dx.doi.org/10.3390/cimb45070340.

Full text

Abstract:

The appropriate dosage of edaravone—a radioprotective agent—and its effect on tumors are unknown. This study evaluated the effects of edaravone on intestinal injuries and tumors in mice induced by whole body X-ray irradiation. Small intestinal mucositis was induced in C3H/HeNSlc mice using a single X-ray dose (15 Gy). Edaravone (15, 30, and 100 mg/kg) was administered 30 min before irradiation to evaluate its protective effect. After 3.5 days, the jejunum was removed and the histological changes were evaluated. Next, C3H/HeNSlc mice with squamous cell carcinoma VII tumors were provided the sam

APA, Harvard, Vancouver, ISO, and other styles

28

Houzen, Hideki, Takahiro Kano, Kazuhiro Horiuchi, Masahiro Wakita, Azusa Nagai, and Ichiro Yabe. "Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan." Pharmaceuticals 14, no. 8 (2021): 705. http://dx.doi.org/10.3390/ph14080705.

Full text

Abstract:

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tr

APA, Harvard, Vancouver, ISO, and other styles

29

Halushko, O. A. "Application of a free radical scavenger edaravone in patients with hemorrhagic stroke." Infusion & Chemotherapy, no. 1 (March 25, 2021): 28–36. http://dx.doi.org/10.32902/2663-0338-2021-1-28-36.

Full text

Abstract:

BACKGROUND. The free radical scavenger edaravone helps to reduce the area of ischemic injury and improve the longterm effects of stroke, and is therefore widely used in the treatment of ischemic stroke. However, the role of edaravone in the treatment of hemorrhagic stroke patients has not yet been clarified. OBJECTIVE. To investigate the feasibility and effectiveness of the use of the free radical scavenger edaravone in the treatment of patients with acute hemorrhagic stroke. MATERIALS AND METHODS. A search was conducted for studies and systematic reviews for the keywords “acute st

APA, Harvard, Vancouver, ISO, and other styles

30

Kara, Ozlem, and Asuman Kilitci. "Antioxidant and Apoptotic Effect of Edaravone on Cisplatin-Induced Brain Injury in Rats." Acta Neurologica Taiwanica 33, no. 1 (2024): 9–12. http://dx.doi.org/10.4103//ant.33-1_111_0067.

Full text

Abstract:

Purpose: This study aims to investigate the effect of edaravone in preventing cisplatin-induced brain damage. Methods: Forty female Wistar albino rats were included in the study. 4 groups were created. In group 1 (control group) (n=10), neither any drugs were given nor anything was performed. Group 2 (cisplatin group) (n=10), single dose 7.5 mg/kg cisplatin was given. In group 3 (edaravone group) (n=10), single dose 1 mg/kg edaravone was administered. Group 4 (cisplatin+ edaravone group) (n=10), single dose 7.5 mg/kg cisplatin and 1 mg/kg edaravone were given. Brain tissue was removed in all r

APA, Harvard, Vancouver, ISO, and other styles

31

Ceber, Mehmet, Ilker Akar, Ilker Ince, Cemal Aslan, and Sameh Alagha. "The effect of Edaravone on lung injury after lower limb ischemiareperfusion in a rat model: Biochemical and histopathological insights." Turkish Journal of Vascular Surgery 32, no. 3 (2023): 166–73. http://dx.doi.org/10.9739/tjvs.2023.08.023.

Full text

Abstract:

Aim: Lower limb ischemia/reperfusion leads to distant organ dysfunction, notably affecting the lungs, resulting in respiratory failure and significant morbidity and mortality. Edaravone is a new free radical scavenger and has attracted the attention of researchers. This study aims to examine edaravone's influence on lung injury arising from lower limb ischemia-reperfusion. Material and Methods: Forty male Wistar rats were categorized into groups: Sham, Ischemia/Reperfusion (IR), Solvent, and Edaravone. The infrarenal abdominal aorta was clamped for 120 minutes and then reperfused for another 1

APA, Harvard, Vancouver, ISO, and other styles

32

Singh, Priya, Paul Belliveau, Jennifer Towle, Andrea Elena Neculau, and Lorena Dima. "Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis." American Journal of Therapeutics 31, no. 3 (2024): e258-e267. http://dx.doi.org/10.1097/mjt.0000000000001742.

Full text

Abstract:

Background: Amyotrophic lateral sclerosis (ALS) is characterized by loss of motor neurons due to degeneration of nerve cells within the brain and spinal cord. Early symptoms include limb weakness, twitching or muscle cramping, and slurred speech. As the disease progresses, difficulty breathing, swallowing, and paralysis can lead to death. Currently, there are no medications that cure ALS, and guidelines recommend treatments focused on symptom management. Intravenous (IV) edaravone was approved by the US Food and Drug Administration (FDA) in 2017 as a treatment to slow the progression of ALS. I

APA, Harvard, Vancouver, ISO, and other styles

33

Ren, Haiyan, Lijuan Ma, Xueli Gong та ін. "Edaravone exerts brain protective function by reducing the expression of AQP4, APP and Aβ proteins". Open Life Sciences 14, № 1 (2019): 651–58. http://dx.doi.org/10.1515/biol-2019-0074.

Full text

Abstract:

AbstractThis study aims to investigate the changes of aquaporin-4 (AQP4), β-amyloid precursor proteins (APP) and β-amyloid (Aβ) in brain tissues after cerebral ischemiareperfusion injury (CIRI), and evaluate the effect of edaravone. The Middle Cerebral Artery Occlusion was used to establish CIRI in rats. Rats were divided into control, model and edaravone groups. The neurological deficits in the model group were obvious and the neurological score increased compared to the control group, while the neurological deficits of the edaravone group were improved as the neurological score decreased com

APA, Harvard, Vancouver, ISO, and other styles

34

Mikayil Aliyev, Mirza, Ulduz Yunis Safarova, and Shafiqa Jahangir Jafarova. "CHARACTERISTICS AND THERAPEUTIC EFFECTS OF THE NOVEL FREE RADICAL SCAVENGER – EDARAVONE." NATURE AND SCIENCE 04, no. 05 (2020): 17–20. http://dx.doi.org/10.36719/2707-1146/05/17-20.

Full text

Abstract:

Edaravone is the first free radical scavenger which approved clinically and has an ability to decrease the level of free radicals in cells. Edaravone is a strong antioxidant, which can protect different cells (e.g. endothelial cells) against damage by ROS by inhibiting the lipoxygenase metabolism of arachidonic acid, by trapping hydroxyl radicals, by increasing prostacyclin production, by inhibiting alloxan-induced lipid peroxidation, etc. Because of that, Edaravone is used in treatment of diseases which are associated with oxidative stress. Key words: edaravone, free radical, antioxidant, neu

APA, Harvard, Vancouver, ISO, and other styles

35

Halushko, O. A. "New and little-known possibilities of edaravone in the treatment of cerebral stroke and extracranial pathology." Infusion & Chemotherapy, no. 3 (September 29, 2023): 36–42. http://dx.doi.org/10.32902/2663-0338-2023-3-36-42.

Full text

Abstract:

BACKGROUND. Edaravone is a free radical scavenger and inhibits lipid peroxidation and thus reduces oxidative damage to brain cells and other organs. Edaravone is mainly known as an effective agent in the treatment of ischemic stroke and amyotrophic lateral sclerosis. OBJECTIVE. To investigate the little-known possibilities of edaravone when it is used in clinical practice. MATERIALS AND METHODS. To solve the task, a search and analysis of full-text articles was conducted in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted using the key word

APA, Harvard, Vancouver, ISO, and other styles

36

Takahashi, Ryosuke. "Edaravone in ALS." Experimental Neurology 217, no. 2 (2009): 235–36. http://dx.doi.org/10.1016/j.expneurol.2009.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mankovsky, Boris, and Oleksandr Halushko. "Will edaravone become a new complex treatment for diabetes?" Diabetes Obesity Metabolic Syndrome, no. 4 (August 28, 2023): 15–22. http://dx.doi.org/10.57105/2415-7252-2023-4-01.

Full text

Abstract:

Edaravone is a low molecular weight antioxidant that scavenges free radicals and inhibits lipid peroxidation, thereby reducing oxidative damage to brain cells and other organs. Edaravone is mainly known as an effective agent in the treatment of ischemic stroke and amyotrophic lateral sclerosis. The aim: to investigate the possibilities of edaravone in its use in the treatment of patients with diabetes. Materials and methods. To solve the task, a search and analysis of full-text articles was conducted in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted

APA, Harvard, Vancouver, ISO, and other styles

38

Su, Li, Shengshan Yuan, Xinhan Yang, and Yongming Jiang. "Effect of butylphthalide combined with edaravone d borneol on efficacy in elderly patients with acute cerebral infarction." Tropical Journal of Pharmaceutical Research 22, no. 3 (2023): 665–71. http://dx.doi.org/10.4314/tjpr.v22i3.25.

Full text

Abstract:

Purpose: To investigate the efficacy of butylphthalide combined with edaravone d-borneol in elderly patients with acute cerebral infarction. Methods: From October 2020 - October 2021, 166 elderly patients suffering from acute cerebral infarction in Affiliated Hospital of Youjiang Medical College for Nationalities, Baise City, China were selected as the study subjects, and randomly divided into study and control groups, respectively, with 83 patients each. Control group was treated with edaravone d-borneol injection (15 mL of edaravone d-borneol in 100 mL of saline), while the study group was t

APA, Harvard, Vancouver, ISO, and other styles

39

Zhang, Shan-Jing, Jian-Ming Ni, Guo-Rong Ding, Yan-Zhong Xie, and Yan-Liang Tang. "Edaravone Protects Nerve Synapse Damage in Alzheimer’s Disease via Regulating Rho (Ras Homologue)/Rho-Associated Protein Kinase (Rho/ROCK) Pathway." Journal of Biomaterials and Tissue Engineering 11, no. 7 (2021): 1352–57. http://dx.doi.org/10.1166/jbt.2021.2698.

Full text

Abstract:

Edaravone regulates Rho/ROCK signaling pathway and its relationship with Alzheimer’s disease (AD) damage repair remains unclear. Our study aims to explore the protective mechanism of edar-avone on Alzheimer Disease nerve synapses. The Alzheimer Disease animal mouse model was established followed by analysis of hippocampal synaptic damage by Congo red stain and Golgi’s method, Morris water maze assay, levels of postsynaptic density mRNA 95 antibody (PSD95) and synapse-associated mRNA synapsin 1 (SYN1) in the hippocampus. Edaravone can improve the behavior of mice, including spatial learning and

APA, Harvard, Vancouver, ISO, and other styles

40

Yamashita, Toru, and Koji Abe. "Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases." International Journal of Molecular Sciences 25, no. 5 (2024): 2945. http://dx.doi.org/10.3390/ijms25052945.

Full text

Abstract:

The brain is susceptible to oxidative stress, which is associated with various neurological diseases. Edaravone (MCI-186, 3-methyl-1 pheny-2-pyrazolin-5-one), a free radical scavenger, has promising effects by quenching hydroxyl radicals (∙OH) and inhibiting both ∙OH-dependent and ∙OH-independent lipid peroxidation. Edaravone was initially developed in Japan as a neuroprotective agent for acute cerebral infarction and was later applied clinically to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. There is accumulating evidence for the therapeutic effects of edaravone in

APA, Harvard, Vancouver, ISO, and other styles

41

LeBlanc, Alexandre, Miroslava Cuperlovic-Culf, Pier Jr Morin, and Mohamed Touaibia. "Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties." CNS & Neurological Disorders - Drug Targets 18, no. 10 (2020): 779–90. http://dx.doi.org/10.2174/1871527318666191114092007.

Full text

Abstract:

Background:: The current therapeutic options available to patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) are limited and edaravone is a compound that has gained significant interest for its therapeutic potential in this condition. Objectives: : The current work was thus undertaken to synthesize and characterize a series of edaravone analogues. Methods: A total of 17 analogues were synthesized and characterized for their antioxidant properties, radical scavenging potential and copper-chelating capabilities. Results: Radical scavenging and copper-chelating properties were notably ob

APA, Harvard, Vancouver, ISO, and other styles

42

Sucha, Martina, Simona Benediktova, Filip Tichanek, et al. "Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1." International Journal of Molecular Sciences 24, no. 13 (2023): 10689. http://dx.doi.org/10.3390/ijms241310689.

Full text

Abstract:

Edaravone is a mitochondrially targeted drug with a suggested capability to modify the course of diverse neurological diseases. Nevertheless, edaravone has not been tested yet in the context of spinocerebellar ataxia 1 (SCA1), an incurable neurodegenerative disease characterized mainly by cerebellar disorder, with a strong contribution of inflammation and mitochondrial dysfunction. This study aimed to address this gap, exploring the potential of edaravone to slow down SCA1 progression in a mouse knock-in SCA1 model. SCA1154Q/2Q and healthy SCA12Q/2Q mice were administered either edaravone or s

APA, Harvard, Vancouver, ISO, and other styles

43

Badillo, Stephanie Patricia, and Jose Navarro. "Safety of edaravone in acute ischemic stroke: A systematic review and meta-analysis." Neurology Asia 28, no. 1 (2023): 39–53. http://dx.doi.org/10.54029/2023pwf.

Full text

Abstract:

Background & Objective: Stroke is a major cause of death and disability, however many patients do not benefit from time-limited reperfusion therapies. Edaravone is a neuroprotective agent that has been shown to improve neurologic impairment after ischemic stroke. This paper aims to review and synthesize evidence on the safety of edaravone in acute ischemic stroke. Methods: This is a systematic review and meta-analysis of randomized controlled trials and observational studies on the use of edaravone with standard stroke treatment, versus standard stroke treatment alone, among patients with

APA, Harvard, Vancouver, ISO, and other styles

44

Govindarajan, Raghav, Alexis Peters, and Tejas Mehta. "Clinical Experience of Edaravone in Amyotrophic Lateral Sclerosis." RRNMF Neuromuscular Journal 1, no. 2 (2020): 3–6. http://dx.doi.org/10.17161/rrnmf.v1i2.13554.

Full text

Abstract:

Objective: To describe clinical experience with edaravone in ALS over a period of 12 months Methods:The current study retrospectively investigated characteristics in a group of patients (n=31) with ALS who underwent edaravone treatment. Information including age, gender, race, and site of onset of symptoms were collected for all patients. Adverse events with edaravone therapy was documented where available. Results:The average age of the patients observed was 62.09 years, with 18 males and 13 females. 18 patients had limb onset, 12 bulbar onset, and 1 diaphragmatic onset. 7 of the 31 pat

APA, Harvard, Vancouver, ISO, and other styles

45

Fan, Ying, Wen Wu, Yu Lei, et al. "Edaravone-Loaded Alginate-Based Nanocomposite Hydrogel Accelerated Chronic Wound Healing in Diabetic Mice." Marine Drugs 17, no. 5 (2019): 285. http://dx.doi.org/10.3390/md17050285.

Full text

Abstract:

Refractory wound healing is one of the most common complications of diabetes. Excessive production of reactive oxygen species (ROS) can cause chronic inflammation and thus impair cutaneous wound healing. Scavenging these ROS in wound dressing may offer effective treatment for chronic wounds. Here, a nanocomposite hydrogel based on alginate and positively charged Eudragit nanoparticles containing edaravone, an efficient free radical scavenger, was developed for maximal ROS sequestration. Eudragit nanoparticles enhanced edaravone solubility and stability breaking the limitations in application.

APA, Harvard, Vancouver, ISO, and other styles

46

Gautam, Sadhana, and Shagufta Khan. "Investigation of Edaravone Degradation and Stabilization through Solid Dispersions with Kollidone VA64." International Journal of Pharmaceutical Quality Assurance 15, no. 03 (2024): 2041–48. https://doi.org/10.25258/ijpqa.15.3.140.

Full text

Abstract:

Edaravone (EDA) is an effective antioxidant that is easily degraded, which diminishes its therapeutic efficiency. The present study assessed the hydrolytic and oxidative degradation of edaravone and its solid dispersion with Kollidon VA 64, a water-soluble polymer. The characterization of the edaravone and solid dispersion was done by Fourier Transform Infrared Spectroscopy, X-ray diffraction, and Differential Scanning Calorimetry. The results revealed that edaravone undergoes extensive degradation under hydrolytic conditions at pH 2, 5, 7, 10 with the following respective rate constant K: 0.0

APA, Harvard, Vancouver, ISO, and other styles

47

Singh, Sanjiv, and Abhishek Kumar. "Protective Effect of Edaravone on Cyclophosphamide Induced Oxidative Stress and Neurotoxicity in Rats." Current Drug Safety 14, no. 3 (2019): 209–16. http://dx.doi.org/10.2174/1574886314666190506100717.

Full text

Abstract:

Background: Cyclophosphamide (CPA) is the most widely prescribed cancer chemotherapeutic agent which shows serious neurotoxic side effect. Generation of reactive oxygen species at the cellular level is the basic mechanism of cyclophosphamide induced neurotoxicity. Edaravone is the synthetic drug used for brain stroke and has potent antioxidant property. Objective: This study aimed to investigate the effect of edaravone on neurobehavioral and neuropathological alteration induced by cyclophosphamide in male rats. Methods: Twenty eight Sprague-Dawley rats were equally divided into four groups of

APA, Harvard, Vancouver, ISO, and other styles

48

Oktay, S., B. Alev, S. Tunali, et al. "Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine." Human & Experimental Toxicology 34, no. 6 (2014): 654–61. http://dx.doi.org/10.1177/0960327114554047.

Full text

Abstract:

Valproic acid (VPA) is a drug used for the treatment of epilepsy, bipolar psychiatric disorders, and migraine. Previous studies have reported an increased generation of reactive oxygen species and oxidative stress in the toxic mechanism of VPA. Edaravone, a free radical scavenger for clinical use, can quench free radical reaction by trapping a variety of free radical species. In this study, effect of edaravone on some small intestine biochemical parameters in VPA-induced toxicity was investigated. Thirty seven Sprague Dawley female rats were randomly divided into four groups. The groups includ

APA, Harvard, Vancouver, ISO, and other styles

49

He, Chao, Wei Zhang, Suobei Li, Wei Ruan, Junmei Xu та Feng Xiao. "Edaravone Improves Septic Cardiac Function by Inducing an HIF-1α/HO-1 Pathway". Oxidative Medicine and Cellular Longevity 2018 (2018): 1–11. http://dx.doi.org/10.1155/2018/5216383.

Full text

Abstract:

Septic myocardial dysfunction remains prevalent and raises mortality rate in patients with sepsis. During sepsis, tissues undergo tremendous oxidative stress which contributes critically to organ dysfunction. Edaravone, a potent radical scavenger, has been proved beneficial in ischemic injuries involving hypoxia-inducible factor- (HIF-) 1, a key regulator of a prominent antioxidative protein heme oxygenase- (HO-) 1. However, its effect in septic myocardial dysfunction remains unclarified. We hypothesized that edaravone may prevent septic myocardial dysfunction by inducing the HIF-1/HO-1 pathwa

APA, Harvard, Vancouver, ISO, and other styles

50

Budianto, Pepi, Diah Kurnia Mirawati, Benedictus B, Kenneth Tan, Muhammad Hafizhan, and Stefanus Erdana Putra. "COMPARISON OF EFFICACY BETWEEN EDARAVONE AND RILUZOLE COMBINATION THERAPY FOR PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS." MNJ (Malang Neurology Journal) 11, no. 1 (2025): 69–77. https://doi.org/10.21776/ub.mnj.2025.011.01.13.

Full text

Abstract:

Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neuromuscular disease with a survival period of less than 5 years. Although the past decade has shown a major growth of interest in Edaravone research due to its superior efficacy, a growing number of research done on Riluzole combinations for ALS therapy. Objective: A systematic review is needed to compare the patient outcomes as shown in the ALS functional rating scale (ALSFRS-R) of Edaravone and Riluzole combinations. Methods: This research is a systematic review from PubMed, ProQuest, and Science Direct. The studies included were r

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!